PT  - JOURNAL ARTICLE
AU  - Wang, Junren
AU  - Zhu, Jianwei
AU  - Yang, Huazhen
AU  - Hu, Yao
AU  - Sun, Yajing
AU  - Ying, Zhiye
AU  - Qu, Yuanyuan
AU  - Valdimarsdóttir, Unnur A
AU  - Fang, Fang
AU  - Song, Huan
TI  - Excess cardiovascular deaths in the beginning of COVID-19 outbreak
AID  - 10.1101/2020.08.29.20184317
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.29.20184317
4099  - http://medrxiv.org/content/early/2020/09/02/2020.08.29.20184317.short
4100  - http://medrxiv.org/content/early/2020/09/02/2020.08.29.20184317.full
AB  - Importance The healthcare demand created by the COVID-19 pandemic was far beyond the hospital surge capacity in many countries, resulting in possible negative influence on prognosis of other severe diseases, such as cardiovascular disease (CVD).Objective To assess the impact of the COVID-19 outbreak on CVD-related hospitalizations and mortality.Design Community-based prospective cohort study.Setting the UK Biobank population.Participants 421,717 UK Biobank participants who were registered in England and alive on December 1st 2019.Main outcomes and measures The primary outcome of interest was CVD death, as deaths with CVD as a cause of death according to the death registers. We retrieved information on hospitalizations with CVD as the primary diagnosis based on the UK Biobank hospital inpatient data. The study period was between December 1st 2019 and May 30th 2020, and we used the same calendar period of the three preceding years as the reference period. Standardized mortality/incidence ratios (SMRs/SIRs) with 95% confidence intervals were used to estimate the relative risk of CVD outcomes during the study period, compared with the reference period, to control for seasonal variations and aging of the study population.Results We observed a distinct increase in CVD-related deaths in March and April 2020 as compared to the corresponding months of the three preceding years. The observed number of CVD death (n=217) was almost doubled in April, compared with the expected number (n=120), corresponding to an SMR of 1.81 (95% CI 1.58-2.06). We observed a sharp decline of CVD hospitalization in March (n=841) and April (n=454), compared with the expected number (n=1208 for March and 1026 for April), leading to an SIR of 0.70 (95% CI 0.65-0.74) for March and 0.44 (95% CI 0.40-0.48) for April. There was also a clear increase of death, but a clear decrease of hospitalization, in March and April for all the five major subtypes of CVD.Conclusions We observed a distinct excess in CVD deaths in the beginning of the COVID-19 outbreak in the UK Biobank population. In addition to CVD complications of SARS-CoV-2 infections, the reduced hospital capacity might have contributed to the observed excess CVD deaths.Question How did the COVID-19 outbreak affect rates of CVD-related death and hospitalization?Finding In this prospective study involving 421,717 UK Biobank participants, we observed excess CVD-related mortality in parallel with decreased CVD-related hospitalization in the beginning of the COVID-19 pandemic, March and April 2020.Meaning In addition to severe SARS-CoV-2 infection progressing to CVD-related death, reduced hospital resources might have partially contributed to the excess CVD mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding: This work is supported by the National Science Foundation of China (No. 81971262 to HS), West China Hospital COVID-19 Epidemic Science and Technology Project (No. HX-2019-nCoV-014 to HS), and Sichuan University Emergency Grant (No. 2020scunCoVyingji1002 to HS). Role of Funder/Sponsor: The sponsors had no role in the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the biomedical research ethics committee of West China Hospital (reference number: 2020.661).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing: Data from UK Biobank (http://www.ukbiobank.ac.uk/) are available to all researchers upon application. This research has been conducted using the UK Biobank Resource under Application 54803. http://www.ukbiobank.ac.uk/